Crowdonomics
Zimmerman BioPharma Holding, Inc.

Reg A+ · Equity · Mar 2020

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$0 / $12.6M max
0% of ceiling
Investors
—
—
Estimated pre-money
$126M
—

Financials disclosed in this offering

FY2018 · hover for source
$1.4M
−$8K
FY2018
RevenueNet income
Metric
FY2018
Income statement
Revenue
$1,415,640
Cost of goods sold
$852,621
Gross margin
40%
Net income
-$7,959
Balance sheet
Cash
$0
Accounts receivable
$0
Total assets
$0
Long-term debt
$0
Total liabilities
$125,000
Other
Headcount
2

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Jul 10, 2020
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Jun 5, 2020
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$126M
Price / share$0.18
Shares offered70,000,000

Estimated, not stated: $0.18 × 699,991,000 securities outstanding.

Offering details

Target—
Max$12,600,000
Min investment—
OpenedMar 5, 2020
Deadline—
ClosedNov 6, 2020
Days active246

Links & provenance

Source: SEC EDGAR
0001575705-20-000019
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.